164 related articles for article (PubMed ID: 35715162)
1. Endometrial Cancer: An Update on Prognostic Pathologic Features and Clinically Relevant Biomarkers.
Li JJX; Ip PPC
Surg Pathol Clin; 2022 Jun; 15(2):277-299. PubMed ID: 35715162
[TBL] [Abstract][Full Text] [Related]
2. Classification of Endometrial Carcinoma: New Perspectives Beyond Morphology.
Akhtar M; Al Hyassat S; Elaiwy O; Rashid S; Al-Nabet ADMH
Adv Anat Pathol; 2019 Nov; 26(6):421-427. PubMed ID: 31567131
[TBL] [Abstract][Full Text] [Related]
3. Molecular Pathology: Predictive, Prognostic, and Diagnostic Markers in Uterine Tumors.
Ritterhouse LL; Howitt BE
Surg Pathol Clin; 2016 Sep; 9(3):405-26. PubMed ID: 27523969
[TBL] [Abstract][Full Text] [Related]
4. Endometrial Carcinoma Diagnosis: Use of FIGO Grading and Genomic Subcategories in Clinical Practice: Recommendations of the International Society of Gynecological Pathologists.
Soslow RA; Tornos C; Park KJ; Malpica A; Matias-Guiu X; Oliva E; Parkash V; Carlson J; McCluggage WG; Gilks CB
Int J Gynecol Pathol; 2019 Jan; 38 Suppl 1(Iss 1 Suppl 1):S64-S74. PubMed ID: 30550484
[TBL] [Abstract][Full Text] [Related]
5. Activated leukocyte cell adhesion molecule (ALCAM) is a marker of recurrence and promotes cell migration, invasion, and metastasis in early-stage endometrioid endometrial cancer.
Devis L; Moiola CP; Masia N; Martinez-Garcia E; Santacana M; Stirbat TV; Brochard-Wyart F; García Á; Alameda F; Cabrera S; Palacios J; Moreno-Bueno G; Abal M; Thomas W; Dufour S; Matias-Guiu X; Santamaria A; Reventos J; Gil-Moreno A; Colas E
J Pathol; 2017 Mar; 241(4):475-487. PubMed ID: 27873306
[TBL] [Abstract][Full Text] [Related]
6. High-grade endometrial carcinomas: Morphologic spectrum and molecular classification.
Zhang C; Zheng W
Semin Diagn Pathol; 2022 May; 39(3):176-186. PubMed ID: 34852949
[TBL] [Abstract][Full Text] [Related]
7. Molecular staging of gynecological cancer: What is the future?
Binder PS; Prat J; Mutch DG
Best Pract Res Clin Obstet Gynaecol; 2015 Aug; 29(6):776-89. PubMed ID: 25934522
[TBL] [Abstract][Full Text] [Related]
8. Reproducibility of grading systems for endometrial endometrioid carcinoma and their relation with pathologic prognostic parameters.
Kapucuoglu N; Bulbul D; Tulunay G; Temel MA
Int J Gynecol Cancer; 2008; 18(4):790-6. PubMed ID: 17892460
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological significance of PSF3 expression in uterine endometrial carcinomas.
Park JK; Otsuka N; Tomaru U; Suzuki H; Azuma M; Okamoto K; Yamashiro K; Kasahara M
Hum Pathol; 2018 Oct; 80():104-112. PubMed ID: 29936059
[TBL] [Abstract][Full Text] [Related]
10. Identifying aggressive forms of endometrioid-type endometrial cancer: new insights into molecular subtyping.
Liu Y; Broaddus RR; Zhang W
Expert Rev Anticancer Ther; 2015 Jan; 15(1):1-3. PubMed ID: 25494844
[TBL] [Abstract][Full Text] [Related]
11. [Immunohistochemical and molecular pathological typing in the differential diagnosis and prognosis risk assessment of endometrial carcinoma].
Wang MH; Hui P
Zhonghua Bing Li Xue Za Zhi; 2021 Sep; 50(9):1078-1082. PubMed ID: 34496509
[TBL] [Abstract][Full Text] [Related]
12. Dedifferentiated endometrial carcinomas with neuroendocrine features: a clinicopathologic, immunohistochemical, and molecular genetic study.
Espinosa I; De Leo A; D'Angelo E; Rosa-Rosa JM; Corominas M; Gonzalez A; Palacios J; Prat J
Hum Pathol; 2018 Feb; 72():100-106. PubMed ID: 29133142
[TBL] [Abstract][Full Text] [Related]
13. Molecular approaches for classifying endometrial carcinoma.
Piulats JM; Guerra E; Gil-Martín M; Roman-Canal B; Gatius S; Sanz-Pamplona R; Velasco A; Vidal A; Matias-Guiu X
Gynecol Oncol; 2017 Apr; 145(1):200-207. PubMed ID: 28040204
[TBL] [Abstract][Full Text] [Related]
14. High-Grade Endometrial Carcinomas: Classification with Molecular Insights.
Carlson JW; Nastic D
Surg Pathol Clin; 2019 Jun; 12(2):343-362. PubMed ID: 31097108
[TBL] [Abstract][Full Text] [Related]
15. A Timely Update of Immunohistochemistry and Molecular Classification in the Diagnosis and Risk Assessment of Endometrial Carcinomas.
Wang M; Hui P
Arch Pathol Lab Med; 2021 Nov; 145(11):1367-1378. PubMed ID: 34673912
[TBL] [Abstract][Full Text] [Related]
16. POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium.
Meng B; Hoang LN; McIntyre JB; Duggan MA; Nelson GS; Lee CH; Köbel M
Gynecol Oncol; 2014 Jul; 134(1):15-9. PubMed ID: 24844595
[TBL] [Abstract][Full Text] [Related]
17. Association of mammalian target of rapamycin with aggressive type II endometrial carcinomas and poor outcome: a potential target treatment.
Peiró G; Peiró FM; Ortiz-Martínez F; Planelles M; Sánchez-Tejada L; Alenda C; Ceballos S; Sánchez-Payá J; Laforga JB
Hum Pathol; 2013 Feb; 44(2):218-25. PubMed ID: 22955108
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological features and prognostic significance of CTNNB1 mutation in low-grade, early-stage endometrial endometrioid carcinoma.
Ruz-Caracuel I; López-Janeiro Á; Heredia-Soto V; Ramón-Patino JL; Yébenes L; Berjón A; Hernández A; Gallego A; Ruiz P; Redondo A; Peláez-García A; Mendiola M; Hardisson D
Virchows Arch; 2021 Dec; 479(6):1167-1176. PubMed ID: 34420090
[TBL] [Abstract][Full Text] [Related]
19. S100A1 expression in ovarian and endometrial endometrioid carcinomas is a prognostic indicator of relapse-free survival.
DeRycke MS; Andersen JD; Harrington KM; Pambuccian SE; Kalloger SE; Boylan KL; Argenta PA; Skubitz AP
Am J Clin Pathol; 2009 Dec; 132(6):846-56. PubMed ID: 19926575
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic potential of differentially regulated microRNAs among endometriosis, endometrioid ovarian cancer, and endometrial cancer.
Kumari P; Sharma I; Saha SC; Srinivasan R; Minhas P
J Cancer Res Ther; 2021; 17(4):1003-1011. PubMed ID: 34528556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
